Deliberazione
Autorizzazione allo studio clinico sperimentale, farmacologico, profit, denominato: “A Multicenter, Randomized, Parallel-group, Doubleblind, Two-arm, Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared with Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive with Systemic Sclerosis” - Codice Protocollo DAISY D3460C00002
N° 598
del 26/10/2023
